3.69

4.90% -0.19

After Hours: 3.69

Lantern Pharma Inc (LTRN)

Overview News Price History Option Chain Financials Discussions Forecast

Lantern Pharma Inc stock is traded at $3.69, with a volume of 197.49K. It is down -4.90% in the last 24 hours and up +17.52% over the past month. Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

Previous Close:

$3.88

Open:

$3.98

24h Volume:

197.49K

Relative Volume:

0.31

Market Cap:

$47.08M

Revenue:

Net Income/Loss:

$-15.91M

P/E Ratio:

-2.5536

EPS:

-1.445

Net Cash Flow:

$-15.07M

1W Performance:

-1.60%

1M Performance:

+17.52%

6M Performance:

+9.50%

1Y Performance:

+20.98%

1-Day Range:

$3.62

$4.10

1-Week Range:

$3.60

$4.1999

52-Week Range:

$1.11

$5.7441

Lantern Pharma Inc Stock (LTRN) Company Profile

Name

Lantern Pharma Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

972-277-1136

Address

1920 MCKINNEY AVENUE, DALLAS, TX

Employee

Twitter

@lanternpharma

Next Earnings Date

2026-05-15

Latest SEC Filings

LTRN's Discussions on Twitter

Compare LTRN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LTRN Lantern Pharma Inc	3.69	49.50M	0	-15.91M	-15.07M	-1.445
VRTX Vertex Pharmaceuticals Inc	450.46	112.92B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.18B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	55.57B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	37.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	32.71B	742.00K	-1.37B	-1.07B	-7.0731

Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-21	Initiated	H.C. Wainwright	Buy

Lantern Pharma Inc Stock (LTRN) Latest News

Jun 12, 2026

Lantern Pharma (LTRN) Falls 4.7% as Biotech Stock Tests Key Support ZoneDividend Growth Stocks - newsline.com

Jun 12, 2026

Lantern Pharma (NASDAQ: LTRN) files S-1 resale and flags funding risk - Stock Titan

Jun 12, 2026

Jun 11, 2026

Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits

Jun 11, 2026

Jun 07, 2026

Lantern Pharma (LTRN) Extends Decline: Key Support Levels in Focus After 5.28% DropRisk Parity Rebalance - newsline.com

Jun 07, 2026

Jun 02, 2026

Lantern Pharma stock jumps on lung cancer trial survival data By Investing.com - Investing.com India

Jun 02, 2026

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer - BioSpace

Jun 02, 2026

Lantern Pharma reports trial data for lung cancer treatment By Investing.com - Investing.com Nigeria

Jun 02, 2026

Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer - TradingView

Jun 02, 2026

Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress - TipRanks

Jun 02, 2026

Jun 01, 2026

Lantern Pharma (LTRN) shares Harmonic LP-300 Phase 2 trial presentation in 8-K - Stock Titan

Jun 01, 2026

Lantern Pharma (LTRN) Slips 4.15%: Testing Key Support Amid Biotech VolatilityGap and Go - newsline.com

Jun 01, 2026

May 29, 2026

Lantern Pharma Edges Higher: LTRN Holds Above Support After 2.57% GainCall Spread Alert - newsline.com

May 29, 2026

LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill

May 29, 2026

May 28, 2026